Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.58 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819314 | 1.00 | HTR1A (0.58) | HTR1ASLC6A2HTR2CSLC6A3SLC6A4 | |
| SCHEMBL7888184 | 1.00 | HTR1A (0.58) | HTR1ASLC6A2HTR2CSLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL2947998 | 0.98 | HTR1A (0.57) | HTR1ASLC6A2HTR2CSLC6A3SLC6A4 | |
| SCHEMBL83377 | 0.90 | HRH1 (0.57) | HTR1ASLC6A2HTR2CSLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL473008 | 0.89 | HRH1 (0.55) | HTR1ASLC6A2HTR2CSLC6A3SLC6A4 | |
| SCHEMBL1230447 | 0.87 | SLC6A2 (0.54) | HTR1ASLC6A2HTR2CSLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3951369 | 0.85 | SLC6A2 (0.53) | HTR1ASLC6A2HTR2CSLC6A3SLC6A4 | |
| SCHEMBL19618927 | 0.84 | HTR1A (0.55) | HTR1ASLC6A2HTR2CSLC6A3SLC6A4 | |
| SCHEMBL13034284 | 0.84 | HTR1A (0.55) | HTR1ASLC6A2HTR2CSLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL3107935 | 0.83 | HTR1A (0.54) | HTR1ASLC6A2HTR2CSLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| CN-116507613-A | Bispecific antagonists of retinol binding protein 4 which stabilize transthyretin tetramer, their preparation and use in the treatment of common age-related complications | 纽约哥伦比亚大学理事会 | 2023-07-28 | — | — | CN | disclosed |
| EP-4181909-A2 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | The Trustees Of Columbia University In The City Of New York (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-2328886-B1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PF MEDICAMENT (FR) | 2016-12-28 | — | — | EP | disclosed |
| US-8980936-B2 | Phenoxy-pyrrolidine derivative and its use and compositions | THESAN PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980936-B2 | Phenoxy-pyrrolidine derivative and its use and compositions | THESAN PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980936-B2 | Phenoxy-pyrrolidine derivative and its use and compositions | THESAN PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140045911-A1 | Phenoxy-Pyrrolidine Derivative and Its Use and Compositions | THESAN PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| EP-2173711-B1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | GRACEWAY PHARMACEUTICALS LLC (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20100247471-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100247471-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010100606-A1 | NOVEL PHENYL IMIDAZOLES AND PHENYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| EP-2173711-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | Graceway Pharmaceuticals, LLC (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2010006962-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010006962-A1 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS | PIERRE FABRE MEDICAMENT (FR) | 2010-01-21 | — | — | WO | disclosed |
| WO-2009019566-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009019566-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2007009236-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045911-A1 | Phenoxy-Pyrrolidine Derivative and Its Use and Compositions | SCD, SCD5, FADS2 | HTR1A 3414/4885SLC6A2 4764/4885HTR2C 3327/4885 |
| US-20100247471-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | SCD, SCD5, FADS2 | HTR1A 3414/4885SLC6A2 4764/4885HTR2C 3327/4885 |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, RBP4, RBP1 | HTR1A 2372/4885SLC6A2 1380/4885HTR2C 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.